Ariel Galapo Kann
Hospital Alemão Oswaldo Cruz · 34 works · 1,390 citations · h-index 11
Top works
- Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
- Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
- Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
- ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
- The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate Cancer
- Renal Medullary Carcinoma Response to Chemotherapy: a Referral Center Experience in Brazil
- 716TiP IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy
- THE BURDEN OF UNCONTROLLED CARDIOVASCULAR RISK FACTORS IN MEN WITH PROSTATE CANCER: A RADICAL PC ANALYSIS
- Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)
- Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC)
- Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries
- Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer
- Exploring the role of novel agents in the treatment of renal cell carcinoma
- Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes
- LBA5 A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA)
- Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA.
- LBA8 IMvigor011: A phase III trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer
- DISEASE-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE BLADDER CANCER WHO HAVE PERSISTENT CIRCULATING TUMOR DNA-NEGATIVE BIOMARKER STATUS POST-CYSTECTOMY: IMVIGOR011 STUDY SURVEILLANCE ANALYSIS
- “Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil”
- Multidisciplinary tumor boards: A prospective study of the impact on patient management in a community-based Brazilian cancer center.